Revenue grows by 15%; Net Profit up 36% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research and Development Organization (CRDMO) today announced its financial results for the third quarter and nine months ended December 31, 2024. Financial Performance: Particulars (₹ crores) Q3FY25 Q3FY24 YoY% 9MFY25 9MFY24 YoY% Revenue
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2024. Key Financial Highlights Q3 FY25 Highlights Revenue from operations at Rs. 52,691 mn, up 17% over last year. Research & Development (R&D) investments for the quarter stood
The conference saw participation from more than 2100 delegates, with over 300 eminent speakers sharing their experiences After last year’s success, the 2025 conference featured the Startup Hub, showcasing innovation in clinical research This year also marks 20 years of ISCR advancing clinical research in India Indian Society
Cricket legend M.S. Dhoni and Emcure Pharma’s Whole-Time Director Namita Thapar have come together in a powerful conversation to highlight the urgent need to prioritize women’s health. A video shared by Namita on her podcast on women’s health, Uncondition Yourself with Namita, highlights how women, despite
Aster India reports steady revenue and EBITDA performance. 9M FY25 revenues up 15% YoY to INR 3,138 Crs; 9M FY25 Operating EBITDA up 35% YoY to INR 613 Crs Q3 FY25 revenues up 11% YoY to Rs. 1,050 Crs.; Operating EBITDA grew 20% to Rs. 202
Cotecna Life Sciences India Private Limited, formerly Geo-Chem Pharma, is proud to announce the inauguration of its new, state-of-the-art laboratory in Mumbai. This development represents a significant step in supporting the rapid growth of India’s pharmaceutical industry and demonstrates Cotecna’s dedication to fostering innovation, quality,
Q3FY2025 Performance Highlights Revenue at ₹11,537m, grew 14.6% YoY Gross margin at ₹6,735m, grew 25.1% YoY EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY US revenue at $73m, grew 13.7% YoY Q3FY25 Reported PAT at ₹900m Reported
Q3FY25 Performance Highlights Revenues of ₹3,926 million grew 18% QoQ. EBITDA grew 85% QoQ to ₹1,432 million. EBITDA margin of 36.5% grew by 1,334 basis points QoQ. Q3 FY25 normalized PAT was ₹898 million, resulting in an EPS of ₹7.8 for the quarter. Reported PAT
The Indian Stroke Association (ISA), in collaboration with the Association of Physicians of India (API), has launched a comprehensive book titled “Advancing Stroke Care in India: Principles and Practices for Physicians” at APICON 2025. This monograph is part of the ongoing Mission Brain Attack, an
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crores Syngene International Limited today announced its third quarter financial results. Reported revenue from operations was up by 11% year-on-year to Rs. 944
